Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EDIT
- Price
- 1.30
- Stock movement up
- +0.19 (17.12%)
- Company name
- Editas Medicine Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 107.31M
- Ent value
- 163.41M
- Price/Sales
- 1.74
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.88%
- 1 year return
- -80.39%
- 3 year return
- -59.62%
- 5 year return
- -42.74%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EDIT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.74 |
| Price to Book | 0.61 |
| EV to Sales | 2.65 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 82.55M |
| EPS (TTM) | -2.55 |
| FCF per share (TTM) | -2.32 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 61.76M |
| Gross profit (TTM) | 55.86M |
| Operating income (TTM) | -228.52M |
| Net income (TTM) | -210.57M |
| EPS (TTM) | -2.55 |
| EPS (1y forward) | -1.64 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 90.46% |
| Operating margin (TTM) | -370.03% |
| Profit margin (TTM) | -340.96% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 95.83M |
| Net receivables | 126.00K |
| Total current assets | 271.14M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 81.68M |
| Total assets | 327.57M |
| Accounts payable | 12.49M |
| Short/Current long term debt | 38.49M |
| Total current liabilities | 72.35M |
| Total liabilities | 151.93M |
| Shareholder's equity | 175.63M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -181.76M |
| Capital expenditures (TTM) | 9.59M |
| Free cash flow (TTM) | -191.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -119.89% |
| Return on Assets | -64.28% |
| Return on Invested Capital | -101.03% |
| Cash Return on Invested Capital | -91.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.10 |
| Daily high | 1.30 |
| Daily low | 1.08 |
| Daily Volume | 3.13M |
| All-time high | 90.58 |
| 1y analyst estimate | 3.78 |
| Beta | 2.01 |
| EPS (TTM) | -2.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| EDIT | S&P500 | |
| Current price drop from All-time high | -98.56% | -12.89% |
| Highest price drop | -98.92% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -58.25% | -11.07% |
| Avg time to new high | 101 days | 12 days |
| Max time to new high | 1070 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
107.31M
Marketcap category
Small-cap
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Employees
265
Investor relations
SEC filings
CEO
Cynthia L. Collins
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page